Current Clinical Trials and Studies

CADRe faculty researchers are engaged in a variety of different human-oriented research studies. See the listings below and click on the links for more information.

Portrait of Parastoo Fazeli

Parastoo Fazeli, MD

Astrazeneca: The Tulip SLE Study (Recruiting)

The goal of the Tulip SLE Study is to find out whether anifrolumab, an investigational drug, may help reduce symptoms of lupus and limit the need for other medications. During the study period, participants will be allowed to take their currently prescribed lupus medications.

Portrait of Brian Fife

Brian Fife, PhD

Reversing Tissue Fibrosis Study (Recruiting)

This study was designed to test the hypothesis that treatment of HIV infected subjects with losartan, an agent with specific anti-inflammatory and anti-fibrotic actions, will:

  1. reverse existing lymphoid tissue fibrosis,
  2. restore lymphoid tissue architecture,
  3. increase the number and improve the function of peripheral and lymphatic CD4 T cells,
  4. decrease levels of systemic immune activation (IA),
  5. decrease size of the HIV reservoir, and
  6. be safe and well tolerated.


Portrait of Jerry Molitor

Jerry Molitor, MD, PhD

StopRA Study (Soon to Be Recruiting)

The purpose of this study is to determine if hydroxychloroquine (HCQ) is safe and effective for the prevention of future onset of rheumatoid arthritis (RA) in individuals who have elevations of an autoantibody, anti-cyclic citrullinated peptide (anti-CCP).

ASSET Study (Recruiting)

The study hypothesis is that SC abatacept is safe and shows evidence of efficacy (improvement in modified Rodnan score [mRSS]) in patients with diffuse cutaneous systemic sclerosis (dcScc) compared to matching placebo.

SSc-PAH Study (Recruiting)

Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is a serious, life-threatening manifestation of systemic sclerosis (SSc), an autoimmune disease of the connective tissue characterized by scarring (fibrosis) and atrophy of the skin, joints and tendons, skeletal muscles, and internal organs, and immunological disturbances. One-year survival for patients with SSc-PAH ranges from 50-81%. There is currently no cure for SSc-PAH and treatment is limited to vasodilator therapy used in all forms of PAH. In recent studies, immunotherapy was shown to be effective in treating SSc-interstitial lung disease, another serious, life-threatening manifestation of SSc. In addition, there are compelling pre-clinical data and anecdotal clinical reports that suggest modulation of the immune system may be an effective strategy for treating SSc-PAH. To test this approach, this trial will determine if rituximab, an immunotherapy, has a marked beneficial effect on clinical disease progression, with minimal toxicity, in patients with SSc-PAH when compared to placebo.


Portrait of Daniel Mueller

Daniel Mueller, MD

Detection of Pathological Lymphocytes Study (Recruiting)

This study will help the investigators design a method to detect the disease-causing immune cells in patients with rheumatoid arthritis (RA). Such methods are not currently available, but if successful, would help scientists to better understand the causes of RA.